19 May 2013
Keywords: novartis, vacc, beats, menactra, ph, iii, trials
Article | 12 May 2008
Swiss drug major Novartis reports its candidate Menveo (MenACWY-CRM), indicated to treat four strains of meningitis, performed better in
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 May 2008
5 May 2008
17 May 2013
© 2013 thepharmaletter.com